It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
POEM (Patient-Oriented Evidence that Matters) intervention is performed as an open
prospective randomized two medical centres trial in subjects suffering from COVID-19 who have
been receiving iRAS, either ACEi, ARB or DRi as basic antihypertensive therapy.
COVID-19 is confirmed by a PCR test, the disease follow-up is divided into 2 periods: up to
12 weeks and up to 24 weeks.
Primary Outcome Measure: BP was known one week before COVID-19 and is tested during the
disease onset on weeks 2, 4, 12, 24. Secondary Outcome Measures are clinical features.
Subanalysis in patients with CKD is additionally performed for those who have CKD.
Drug: Angiotensin converting enzyme inhibitor
routine drug intake
Other Name: no other drug as RAS inhibitor
Drug: Angiotensin Receptor Blockers
routine drug intake
Other Name: no other drug as RAS inhibitor
Drug: Direct renin inhibitor
routine drug intake
Other Name: no other drug as RAS inhibitor
Inclusion Criteria:
- Hypertensive person, stage 1-2
Exclusion Criteria:
- Hypertensive subjects, stage 3, HF (NYHA) 3-4
Medical Practice Prof D.Ivanov
Kiev, Please Select, Ukraine
Iryna Zavalna, MD, Study Chair
Nephrology clinic